1
|
Gao F, Huang G, Xiao J. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship. Med Res Rev 2020; 40:2049-2084. [PMID: 32525247 DOI: 10.1002/med.21698] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Revised: 05/19/2020] [Accepted: 05/24/2020] [Indexed: 12/14/2022]
Abstract
The continuous emergency of drug-resistant cancers and the low specificity of anticancer agents have been the major challenges in the control and treatment of cancer, making an urgent need to develop novel anticancer agents with high efficacy. Chalcones, precursors of flavonoids and isoflavonoids, exhibit structural heterogeneity and can act on various drug targets. Chalcones which demonstrated potential in vitro and in vivo activity against both drug-susceptible and drug-resistant cancers, are useful templates for the development of novel anticancer agents. Hybridization of chalcone moiety with other anticancer pharmacophores could provide the hybrids which have the potential to overcome drug resistance and improve the specificity, so it represents a promising strategy to develop novel anticancer agents. This review emphasizes the development, the mechanisms of action as well as structure-activity relationships of chalcone hybrids with potential therapeutic application for many cancers in recent 10 years.
Collapse
Affiliation(s)
- Feng Gao
- State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.,Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| | - Gang Huang
- Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| | - Jiaqi Xiao
- State Key Laboratory of Biobased Material and Green Papermaking (LBMP), Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.,Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China
| |
Collapse
|
2
|
Fu DJ, Hou YH, Zhang SY, Zhang YB. Efficient click reaction towards novel sulfonamide hybrids by molecular hybridization strategy as antiproliferative agents. J CHEM SCI 2018. [DOI: 10.1007/s12039-017-1415-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Design and Antiproliferative Evaluation of Novel Sulfanilamide Derivatives as Potential Tubulin Polymerization Inhibitors. Molecules 2017; 22:molecules22091470. [PMID: 28872607 PMCID: PMC6151726 DOI: 10.3390/molecules22091470] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 08/21/2017] [Accepted: 08/31/2017] [Indexed: 01/28/2023] Open
Abstract
A series of sulfanilamide-1,2,3-triazole hybrids were designed by a molecular hybridization strategy and evaluated for antiproliferative activity against three selected cancer cell lines (MGC-803, MCF-7 and PC-3). The detailed structure-activity relationships for these sulfanilamide-1,2,3-triazole hybrids were investigated. All these sulfanilamide-1,2,3-triazole hybrids exhibited moderate to potent activity against all cell lines. In particular 4-methyl-N-((1-(3-phenoxybenzyl)-1H-1,2,3-triazol-4-yl)methyl)benzenesulfonamide (11f) showed the most potent inhibitory effect against PC-3 cells, with an IC50 value of 4.08 μM. Furthermore, the tubulin polymerization inhibitory activity in vitro of compound 11f was 2.41 μM. These sulfanilamide hybrids might serve as bioactive fragments for developing more potent antiproliferative agents.
Collapse
|
4
|
Fu DJ, Liu YC, Yang JJ, Zhang J, Xiong CD, Cao ZS, Yin XX, Wei W, Zhang YB. Design and Synthesis of Sulfonamide-1,2,3-Triazole Derivatives Bearing a Dithiocarbamate Moiety as Antiproliferative Agents. JOURNAL OF CHEMICAL RESEARCH 2017. [DOI: 10.3184/174751917x15027935057950] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A series of nine novel 1-(4′-sulfamoylphenyl)-1,2,3-triazole derivatives bearing a 4-dithiocarbamylmethyl moiety were designed using the molecular hybridisation approach and synthesised by alkyne/azide click chemistry. Most of the synthesised compounds exhibited moderate to good antiproliferative activity against oesophagus, gastric and prostate cancer cell lines, but a compound containing a 4-( t-butoxycarbonyl)piperazinylthiocarbonyl moiety showed the highest activity. Against a prostate cancer cell line, it had an IC50 value of 2.4 μM, about 10-fold more active than 5-flurouracil. This work shows that novel sulfonamide-1,2,3-triazole derivatives bearing a dithiocarbamate moiety linked to a 4-substituted piperazine are promising lead compounds for the development of antitumour agents.
Collapse
Affiliation(s)
- Dong-Jun Fu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Ying-Chao Liu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Jia-Jia Yang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Ji Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Chao-Dong Xiong
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Zhu-Song Cao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Xu-Xu Yin
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Wei Wei
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| | - Yan-Bing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou 450001, P.R. China
- Key Laboratory of Technology of Drug Preparation, Zhengzhou University, Ministry of Education, Zhengzhou 450001, P.R. China
- Key Laboratory of Henan Province for Drug Quality and Evaluation, Zhengzhou 450001, P.R. China
| |
Collapse
|
5
|
Fu DJ, Zhao RH, Li JH, Yang JJ, Mao RW, Wu BW, Li P, Zi XL, Zhang QQ, Cai HJ, Zhang SY, Zhang YB, Liu HM. Molecular diversity of phenothiazines: design and synthesis of phenothiazine-dithiocarbamate hybrids as potential cell cycle blockers. Mol Divers 2017; 21:933-942. [PMID: 28785928 DOI: 10.1007/s11030-017-9773-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Accepted: 07/24/2017] [Indexed: 11/28/2022]
Abstract
Novel phenothiazine-dithiocarbamate analogues were designed by molecular hybridization strategy and synthesized and evaluated for their anticancer activity in vitro against three selected cancer cell lines (EC-109, MGC-803, and PC-3). The preliminary structure-activity relationship (SAR) for this phenothiazine-dithiocarbamate hybrids is explored. Among all analogues, 2-oxo-2-(10H-phenothiazin-10-yl)ethyl 4-ethylpiperazine-1-carbodithioate (8a) showed the most potent inhibitory activity with an [Formula: see text] value of [Formula: see text] against PC-3 cells. In addition, compound 8a could arrest the cell cycle at the G1 phase and regulate the expression of G1 checkpoint-related proteins, suggesting that phenothiazine-dithiocarbamate hybrids might be useful as cell cycle blockers.
Collapse
Affiliation(s)
- Dong-Jun Fu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ruo-Han Zhao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Jia-Huan Li
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Jia-Jia Yang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ruo-Wang Mao
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Bo-Wen Wu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Ping Li
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Xiao-Lin Zi
- Pathology and Laboratory Medicine, University of California, Irvine, Orange, CA, 92868, USA
| | - Qing-Qing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Hui-Jie Cai
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China.,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China.,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China
| | - Sai-Yang Zhang
- School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
| | - Yan-Bing Zhang
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. .,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China. .,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China. .,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China.
| | - Hong-Min Liu
- New Drug Research and Development Center, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China. .,Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, China. .,Key Laboratory of Technology of Drug Preparation (Zhengzhou University) Ministry of Education, Zhengzhou, China. .,Key Laboratory of Henan Province for Drug Quality and Evaluation, Henan Province, China.
| |
Collapse
|
6
|
Fu DJ, Zhang SY, Song J, Liu YC, Zhang L, Zhao RH, Zi XL, Liu HM, Zhang YB. Design and Antiproliferative Activity of N-Heterocycle-Chalcone Derivatives. JOURNAL OF CHEMICAL RESEARCH 2016. [DOI: 10.3184/174751916x14740355883191] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Nine chalcone derivatives containing an N-heterocyclic compound attached by its nitrogen atom to one of the benzene rings were prepared and evaluated for their antiproliferative activity against liver, gastric and neuroendocrine cancer cell lines. Most of the synthesised compounds exhibited moderate to good activity against all three cancer cell lines, but in particular, a chalcone containing a 4-(imidazol-1-yl)phenyl group and a 3,4,5-trimethoxyphenyl group showed the highest antiproliferative activity with an IC50 value of 5.39 μM against liver cancer cells.
Collapse
Affiliation(s)
- Dong-Jun Fu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Sai-Yang Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Jian Song
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Yin-Chao Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Li Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Ruo-Han Zhao
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Xiao-Lin Zi
- Pathology and Laboratory Medicine, University of California, Irvine, Orange, California, 95101, USA
| | - Hong-Min Liu
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| | - Yan-Bing Zhang
- Collaborative Innovation Center of New Drug Research and Safety Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, P.R. China
| |
Collapse
|